Key Events This Week
Mar 16: Golden Cross formation signals potential bullish breakout
Mar 17: Mojo Grade upgraded to Hold on technical and valuation improvements
Mar 17: Technical momentum shifts to mildly bullish amid mixed indicators
Mar 20: Week closes at Rs.601.30 (-0.36%)

Lincoln Pharmaceuticals Ltd is Rated Hold
2026-03-28 10:10:03Lincoln Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Lincoln Pharmaceuticals Ltd Upgraded to Hold on Technical and Valuation Improvements
2026-03-17 08:09:37Lincoln Pharmaceuticals Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators, valuation metrics, and financial trends despite some challenges in recent quarterly performance. The upgrade, effective from 16 March 2026, is underpinned by a shift in technical sentiment and a fair valuation stance amid a micro-cap pharmaceutical sector backdrop.
Read full news article
Lincoln Pharmaceuticals Ltd Technical Momentum Shifts to Mildly Bullish Amid Mixed Indicators
2026-03-17 08:00:57Lincoln Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish outlook on weekly charts, despite a recent day decline of 3.87%. This nuanced change is reflected across key technical indicators such as MACD, RSI, moving averages, and Bollinger Bands, signalling a complex but cautiously optimistic scenario for investors in this micro-cap pharmaceutical stock.
Read full news article
Lincoln Pharmaceuticals Ltd Forms Golden Cross, Signalling Potential Bullish Breakout
2026-03-16 18:00:08Lincoln Pharmaceuticals Ltd has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average (DMA) crosses above the 200-DMA. This development often signals a potential bullish breakout, indicating a shift in long-term momentum and a possible trend reversal in the stock’s price trajectory.
Read full news articleWhy is Lincoln Pharmaceuticals Ltd falling/rising?
2026-03-14 01:13:35
Recent Price Movement and Market Context
On 13 March, Lincoln Pharmaceuticals witnessed a notable dip, falling ₹13.95 or 2.26% to close at ₹603.45. This decline forms part of a three-day losing streak during which the stock has shed approximately 4.4% of its value. Intraday, the share price touched a low of ₹596.40, marking a 3.4% drop from recent highs. While the stock remains above its 50-day, 100-day, and 200-day moving averages, it is currently trading below its 5-day and 20-day averages, signalling some short-term weakness.
Despite this recent underperformance, Lincoln Pharmaceuticals has outperformed broader benchmarks over multiple time horizons. Year-to-date, the stock has surged 24.89%, significantly outpacing the Sensex’s decline of 12.50%. Over one year, it ...
Read full news article
Lincoln Pharmaceuticals Ltd is Rated Sell
2026-03-09 10:10:36Lincoln Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.
Read full news article
Lincoln Pharmaceuticals Ltd is Rated Sell
2026-03-08 10:10:26Lincoln Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and technical outlook.
Read full news article
Lincoln Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-03-04 08:01:38Lincoln Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite this, the stock continues to demonstrate pockets of bullishness in key weekly indicators, presenting a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news article





